未來科學大獎（Future Science Prize）是由香港未來科學大獎基金會有限公司發起，北京懷柔未來論壇科技發展中心協辦舉行的評獎活動，旨在獎勵在大中華地區（包含中國大陸地區、香港、澳門及台灣）取得傑出科技成果的科學家  。
2003年度的SARS是生化武器, 他們在SARS爆發前後已經有6000多個專利申請。什麼由動物傳到人, 衹是用來掩飾的藉口.。
"April 28, 2003 — three days after the CDC filed its patent for the SARS coronavirus — Sequoia Pharmaceuticals filed a patent on an antiviral agent for the treatment and control of infectious coronavirus (Patent No. 7151163). So, the CDC files a patent on SARS coronavirus, and three days later there’s a treatment?
This strongly suggests there was a working relationship behind the scenes. Sequoia Pharmaceuticals, founded in 2002, develops antiviral therapeutics with a special focus on drug-resistant viruses.8 Its lead investors include the Wellcome Trust.
But there’s yet another problem with Sequoia’s 2003 filing for an antiviral agent. It was actually issued and published before the CDC patent on SARS coronavirus had been granted, which didn’t happen until 2007, and the CDC had paid to keep the application private. "
The next bombshell revelation occurred on June 5, 2008, when Ablynx, now a part of Sanofi, filed a series of patents detailing what we’ve been told are novel features of SARS-CoV-2, namely the polybasic cleavage site, the spike protein and the ACE2 receptor binding domain. The first of those patents, U.S. Patent No. 9193780, was issued on November 24, 2015. Between 2016 and 2019, a series of patents were issued to Ablynx and Sanofi covering the RNA strands and the subcomponents of the gene strands.
Between 2008 and 2017, a series of patents were also filed by a long list of players, including Crucell, Rubeus Therapeutics, Children’s Medical Corporation, Ludwig-Maximilians-Universität in München, Protein Science Corporation, Dana-Farber Cancer Institute, University of Iowa, University of Hong Kong and the Chinese National Human Genome Center in Shanghai.
This series of patents detail ever single attribute that is supposed to be unique to SARS-CoV-2, according to the paper, “A Novel Bat Coronavirus Reveals Natural Insertions at the S1/S2 2 Cleavage Site of the Spike Protein and a Possible Recombinant 3 Origin of HCoV-19.”
This paper has routinely been used to identify the so-called novel coronavirus that is SARS-CoV-2. Yet there are 73 patents, issued between 2008 and 2019, that describe the very elements that are said to be unique to SARS-CoV-2. Patents have been filed for SARS-CoV-2’s polybasic cleavage site, the ACE2 receptor binding domain, and the spike protein.
“So, there was no ‘outbreak’ of SARS, because we had engineered all of the elements of that,” Martin says. And by 2016, when Baric published a paper warning that SARS coronavirus was “poised for human emergence,” the virus in question had already been patented for commercial exploitation 73 times!